PRAX - Praxis Precision Medicines Inc logo

PRAX

Praxis Precision Medicines Inc

Rev —top 1%5Y
Hold

Praxis Precision Medicines develops therapies for central nervous system disorders using genetic insights. Its portfolio includes small molecule and antisense oligonucleotide candidates for conditions like epilepsy and essential tremor.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago $1,856today

Score Overview

1 Year
Score
Net Growth-11.82%
Net TrendShrank
Net Income Consistency
Rev Growth
Rev TrendShrank
Revenue Consistency
5 Years
Score
Net Growth-103.22%
Net Trend20%
Net Income Consistency
Rev Growth
Rev Trend60%
Revenue Consistency
All Time
Score
Net Growth-448.57%
Net Trend17%
Net Income Consistency
Rev Growth
Rev Trend50%
Revenue Consistency

See the full market ranking →

Praxis Precision Medicines Inc fundamental performance

Across Praxis Precision Medicines Inc's full reported history, from 2020 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 61M to -$ 303M. Revenue increased in 50% of the years measured; net income in 17%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 386.33
1 Year2025-08-12
$ 48.467x
5 Years2021-08-12
$ 208.2085.56%
All Time2020-10-16
$ 417.00-7.35%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 339M$ 758M
2025$ 0.00-$ 303M$ 599M
2024$ 8M-$ 182M$ 392M
2023$ 2M-$ 123M$ 81M
2022$ 1M-$ 213M$ 100M
2021$ 0.00-$ 166M$ 275M
IPO2020$ 0.00-$ 61M$ 296M

Explore beyond PRAX

You're looking at Praxis Precision Medicines Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies